Resource Management & Infrastructure for a Shock Program

Heart failure rarely exists in isolation. Obesity, chronic kidney disease, iron deficiency, and sleep-disordered breathing significantly influence symptom burden, biomarker interpretation, therapeutic response, and clinical outcomes across the heart failure spectrum—particularly in HFpEF. These conditions may act as drivers of disease progression, modifiers of prognosis, or targets for therapy. Emerging data on GLP-1 receptor agonists, cardiorenal therapies, intravenous iron, and positive airway pressure strategies continue to reshape management paradigms while raising important clinical questions.

This session will review contemporary evidence and provide practical guidance on integrating comorbidity-directed strategies into heart failure care.

Learning Objectives

• Recognize how major comorbidities (obesity, CKD, iron deficiency, and sleep-disordered breathing) alter heart failure diagnosis, prognosis, and therapeutic response.
• Apply emerging evidence to tailor heart failure management strategies in patients with overlapping metabolic, renal, hematologic, and respiratory conditions.
• Identify areas of synergy—and tension—between guideline-directed heart failure therapy and comorbidity-directed interventions.